Locations:
November 17, 2026/Neurosciences/Podcast

Developmental and Epileptic Encephalopathies: Essentials of Recognition and Management (Podcast)

Emerging insights underscore a need to look beyond seizures alone

Developmental and epileptic encephalopathies (DEEs) are among the most complex and challenging disorders in pediatric epilepsy. Advances in genetics, precision medicine and multidisciplinary care are reshaping how DEEs are understood and treated as new research reveals that improving outcomes requires looking beyond seizures alone.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

“Years ago, we called this group of epilepsies epileptic encephalopathies, as they were characterized by frequent epileptic spikes on EEG and frequent seizures, which were together considered the direct cause of the neurological, cognitive and developmental symptoms that patients were having, regardless of etiology,” explains Cleveland Clinic pediatric epileptologist Elia Pestana Knight, MD. “Today, that concept has been redefined to acknowledge that the etiology also plays an important role in the development of epileptic discharges and seizures — and also in the neurocognitive and behavioral problems that these patients have.”

In the latest episode of Cleveland Clinic’s Neuro Pathways podcast, Dr. Pestana Knight provides a broad update on current understanding and management of DEEs, exploring the following topics and more:

  • The definition and hallmarks of DEEs
  • Early presentation of DEEs
  • The expanding role of genetics in diagnosis, and how it complements clinical history and imaging
  • The importance of precision treatment to balance seizure control with DEEs’ developmental aspects
  • Therapeutic options and how to factor in genetic considerations
  • Impact on clinical workflow and patient care
  • Sudden unexpected death in epilepsy (SUDEP) in the context of DEEs
  • The importance of multidiscliplinary care

Click the podcast player above to listen to the 30-minute episode now or read on for an edited excerpt of its transcript. Check out more Neuro Pathways episodes at clevelandclinic.org/neuropodcast or wherever you get your podcasts.

Advertisement

This activity has been approved for AMA PRA Category 1 Credit™ and ANCC contact hours. After listening to the podcast, you can claim your credit here.

Excerpt from the podcast

Podcast host Glen Stevens, DO, PhD: How frequently is surgery an option for patients with DEEs?

Elia Pestana Knight, MD: Surgery is an option for some of these patients, particularly those who have structural abnormalities. Therapies start with anti-seizure medications. When those are not enough or when there is a structural lesion, we can do epilepsy surgery — resective epileptic surgery, lesionectomy or hemispherectomy. When those are not possible, we can do corpus callosotomy for patients who are having seizures with significant falls and injuries, particularly in cases that have evolved to the well-known Lennox-Gastaut syndrome. Those patients typically will benefit from that.

And then there is also neuromodulation. You can do vagus nerve neurostimulation or deep brain stimulation or responsive neurostimulation wth the NeuroPace System. These are options that can be offered to these patients.

And for cases with genetic causes, the genetic diagnosis does not preclude the use of neurostimulation techniques. We shy away from epilepsy surgery in these patients because we know, for example, that patients who have a problem with channelopathies — in other words, the genetic mutation leads to channel malfunction — they don’t do as well with epilepsy surgery. These are groups in which we are very focused on precision medicine, such as repurposing drugs with other uses that can be tried for the management of epilepsy. Additionally, of course, we have gene therapy — we all have hope in the development of gene therapy for DEEs.

Advertisement

Dr. Stevens: Among patients who have gene-based abnormalities, are the epilepsies generalized or focal, or a little bit of both?

Dr. Elia Pestana Knight: Both. Patients can have generalized seizures. Or they can have predominantly focal seizures. But they can also have both. And patients may develop a different seizure type across the lifespan, so that they might start with generalized seizures and then develop some focal seizures or focal generalized seizures. Or they might start with a mix of epilepsy phenotypes from the get-go.

Advertisement

Related Articles

stylized illustration of a CAR T receptor

Encouraging 90-Day Results for Allogeneic CAR T-Cell Therapy for Progressive Multiple Sclerosis

Phase 1 trial of azer-cel reports good preliminary safety and efficacy

rendering of new rehab space
November 12, 2026/Neurosciences/PM&R

New Neurology Building to Feature Revolutionary Rehab Technology

Physical, occupational and speech therapists will provide state-of-the-art outpatient care

mosquito on human skin

Rare New Neuroinvasive Threat Identified for Patients on B Cell-Depleting Therapy

Milestone case report expands understanding of infectious risks for those on immunomodulatory therapies

Head shots of Susan Linder and Karen Green
November 3, 2026/Neurosciences/Podcast

Connecting Neuro Rehab Research and Clinical Care (Podcast)

Advanced technologies are changing expectations about what’s possible

illustration of street entrance to a hospital emergency area

Architecture as a Therapeutic Tool: Acute Stroke Care in Our New Neurological Building

A rare opportunity to design for speed, care coordination, recovery and continuous monitoring

Doctor and hospital tech standing next to an older patient in a hospital bed

Inpatient Program Reduced Medication Errors in Patients With Parkinson’s Disease

Multidisciplinary, proactive approach also improved discharge outcomes

floating CAR T cell against background of other cells

Zola-Cel CAR T-Cell Therapy Shows Promising Initial Results in Multiple Sclerosis

Phase 1 Breakfree-2 trial reports good safety and efficacy at week 26

woman in lab holding two vials filled with liquids
October 19, 2026/Neurosciences/Brain Health

CSF and Plasma Analytes Reveal Early Clues to Alzheimer’s Development

Inflammatory protein eotaxin-1 may be a marker of future cognitive decline

Ad